Results 41 to 50 of about 12,338 (219)

Covalent Reprogramming of Kinase Binders to Modulate Protein Abundance

Advanced Science, EarlyView.
Electrophilic remodeling of a broad‐spectrum kinase binder reveals how subtle chemical changes reprogram protein fate. An acrylamide analog of a multi‐kinase binder selectively stabilizes Aurora kinase A (AURKA) by suppressing its ubiquitination, while a short‐linker variant converts this stabilizer into a degrader.
Chen Mozes, Xiaokang Jin, Miguel A. Campos, Chen Zhou, Xiaoyu Zhang   +4 more
wiley   +1 more source

Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.

PLoS ONE, 2010
The proteasome inhibitor bortezomib represents an important advance in the treatment of multiple myeloma (MM). Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of ...
Feng Ge, Chuan-Le Xiao, Li-Jun Bi, Sheng-Ce Tao, Sheng Xiong, Xin-Feng Yin, Li-Ping Li, Chun-Hua Lu, Hai-Tao Jia, Qing-Yu He   +9 more
doaj   +1 more source

Decoding the Mechanism of Action of a Parasite TGFβ Antagonist Inspires the Creation of Cell‐Type‐Specific TGFβ Modulators

Advanced Science, EarlyView.
The mammalian TGFβ interacts with ubiquitously expressed TGFBR1 and TGFBR2, and current TGFβ‐targeting agents are non‐cell‐selective. The cooperative interaction of the modular parasite TGFβ antagonist with multiple host (co‐)receptors empowers the design of TGM chimeras and bispecific antibodies that activate or inhibit TGFβ signaling in a cell ...
Maarten van Dinther, Tristin Schwartze, Jiying Zhang, Kun Fan, Gerard van der Zon, Luke Power, Cynthia S. Hinck, Claire Ciancia, Ananya Mukundan, Roman Gonzalez‐Prieto, Peter van Veelen, Rick M. Maizels, Andrew P. Hinck, Peter ten Dijke   +13 more
wiley   +1 more source

Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma

Case Reports in Hematology, 2016
Bortezomib is a first-generation proteasome inhibitor used in the treatment of multiple myeloma (MM). A few reports have linked bortezomib exposure with the development of thrombotic microangiopathy (TMA).
Jan Van Keer, Michel Delforge, Daan Dierickx, Kathelijne Peerlinck, Evelyne Lerut, Ben Sprangers   +5 more
doaj   +1 more source

ZDHHC18‐Mediated Palmitoylation of ORF3a Promotes SARS‐CoV‐2 Pathogenesis by Antagonizing TRIM16‐Mediated Ubiquitination and Proteasomal Degradation

Advanced Science, EarlyView.
Palmitoylation by ZDHHC18 blocks ORF3a K27‐linked ubiquitination mediated by TRIM16, thereby preventing its proteasomal degradation and strengthening viral pathogenesis. Targeting palmitoylation through a pharmacological inhibitor (2‐BP), a competitive inhibitory peptide (OPIP), or adenovirus‐mediated knockdown of ZDHHC18 expression presents a ...
Sidi Yang, Kun Li, Lihong Liu, Linsen Zeng, Qifeng Deng, Jiacheng Huang, Xiaoran Dong, Xin Wang, Jianwei Liang, Hongchao Liu, Hong Peng, Yuxin Lin, Xiaolu Xie, Yuzhen Ye, Tiefeng Xu, Zhaohuan Wang, Chun‐Mei Li, Deyin Guo   +17 more
wiley   +1 more source

BV173 treatment with 4nM bortezomib.

, 2022
(A+B): Ph+ cells BV173 were treated with DMSO, dasatinib 50nM, bortezomib 4nM and combination at day 0. Viability was measured every 24h to day 5 using PI staining assay. Dasatinib as well as the combination of dasatinib and bortezomib caused a reduction
Margherita Vieri (3482504), Mirle Schemionek (151019), Azam Salimi (13003755), Kema Marlen Schroeder (13003758), Behzad Kharabi Masouleh (13003770), Steffen Koschmieder (106779), Saskia Maletzke (13003764), Tim H. Brümmendorf (9263733), Iris Appelmann (365795)   +8 more
core   +1 more source

Bortezomib-induced muscle toxicity in multiple myeloma [PDF]

, 2017
Multiple myeloma (MM) accounts for ∼13% of all hematologic malignancies. Bortezomib treatment is effective in MM, but can be complicated with neurological side effects.
Valeria Guglielmi, Paolo Manganotti, WILCZYŃSKI, GRZEGORZ, Matteo Marini, VATTEMI, Gaetano Nicola, Giuliano Tomelleri, Sadowski, Radoslaw, MALATESTA, Manuela, Gaetano Vattemi, Wilczynski, Grzegorz M., Radoslaw Sadowski, TINELLI, Martina, Dominika Nowis, Martina Tinelli, Vittorio Meneghini, Vattemi, Gaetano, MENEGHINI, VITTORIO, PAOLI, Laura, MARINI, Matteo, Manganotti, Paolo, TOMELLERI, Giuliano, Laura Paoli, Grzegorz M. Wilczynski, GUGLIELMI, Valeria, Nowis, Dominika, Manuela Malatesta   +25 more
core   +2 more sources

Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy

Experimental Hematology & Oncology, 2012
Peripheral neuropathy (PN) is one of the most common side effects of bortezomib therapy. The majority of bortezomib-related PN is a sensory neuropathy of mild to moderate degree, and is reversible after dose reduction or discontinuation.
Jeter Ashley, Kang Yubin
doaj   +1 more source

ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5

JCI Insight, 2022
The proteasome inhibitors (PIs) bortezomib and carfilzomib, which target proteasome 20S subunit beta 5 (PSMB5) in cells, are widely used in multiple myeloma (MM) treatment.
Yan Yang, Yuhan Gao, Jingcao Huang, Zhuang Yang, Hongmei Luo, Fangfang Wang, Juan Xu, Yushan Cui, Hong Ding, Zhimei Lin, Xinyu Zhai, Ying Qu, Li Zhang, Ting Liu, Lingqun Ye, Ting Niu, Yuhuan Zheng   +16 more
doaj   +1 more source

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

Advanced Science, EarlyView.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng, Chao He, Zhibin He, Hongbo Chen, Fang Cheng, Yongjiang Zheng   +5 more
wiley   +1 more source